Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy



Status:Active, not recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:7 - 13
Updated:4/21/2016
Start Date:February 2012
End Date:September 2016

Use our guide to learn which trials are right for you!

Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201

The primary objective of this study is to assess the ongoing efficacy, safety, and
tolerability of an additional 212 weeks of treatment with eteplirsen injection in Duchenne
muscular dystrophy (DMD) subjects who have successfully completed the 28 week eteplirsen
study: Study 4658-us-201. This study will also evaluate the correlation between biomarkers
for DMD and the clinical status of participating DMD subjects.

This is an open label, multiple dose extension study to assess the ongoing efficacy, safety,
and tolerability of weekly intravenous (IV) infusions of eteplirsen in DMD subjects who have
successfully completed Study 4658-us 201.

Subjects will have the opportunity to enroll in this study during the last visit of Study
4658-us-201 (Week 28). Eligible subjects will receive once weekly IV infusions of eteplirsen
(50 or 30 mg/kg) for an additional 212 weeks. Subjects will receive the same dose of
eteplirsen they received in Study 4658-us-201. Subjects will thereafter continue to receive
once weekly IV infusions of eteplirsen for up to an additional 24 week period (through week
236). If commercial eteplirsen becomes available during this additional 24 week period,
participation in the study will be discontinued as subjects transition to commercial
eteplirsen.

Safety, efficacy, pharmacokinetic (PK), and biomarker assessments will be performed at
scheduled visits; adverse events (AEs) and concomitant medications and therapies will be
continuously monitored.

If review of data from this open label study suggests that continued treatment with
eteplirsen is warranted, this study may be extended by protocol amendment or subjects who
successfully complete this study may have the opportunity to participate in a separate
follow on, open label eteplirsen study.

Inclusion Criteria:

A subject must meet all of the following criteria to be eligible for this study.

1. The subject and/or their parent/legal guardian are willing and able to provide signed
informed consent.

2. The subject has successfully completed 28 weeks of treatment in Study 4658-US-201.

3. The subject has a parent(s) or legal guardian(s) who is able to understand and comply
with all of the study procedure requirements.

Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from this study.

1. The subject has a prior or ongoing medical condition that, in the Investigator's
opinion, could adversely affect the safety of the subject or make it unlikely that the
course of treatment or follow-up would be completed or impair the assessment of study
results.
We found this trial at
11
sites
2801 Atlantic Ave
Long Beach, California 90806
(562) 933-5437
Miller Children's Hospital Miller Children
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
?
mi
from
Liverpool, NY
Click here to add this to my saved trials
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Osceola, Wisconsin 54020
?
mi
from
Osceola, WI
Click here to add this to my saved trials
St. Louis, Missouri 63110
?
mi
from
St. Louis, MO
Click here to add this to my saved trials